HIV treatment study switching to efavirenz
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study tests whether switching to a medication called efavirenz can help control HIV. It is for people who have been on stable HIV treatment for years but still have low levels of virus in their blood.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HIV and are at least 18 years old.
- You have been on HIV treatment for more than 4 years without missing doses.
- Your current HIV treatment does not include a protease inhibitor or booster.
- You have had at least 4 HIV viral loads between 20 and 400 copies/mL in the past 2 years.
- You can add efavirenz to your current HIV medications.
- You are willing to have blood draws or a procedure called leukapheresis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combo pill for HIV (ainuovirine, lamivudine, and tenofovir) against a standard pill (efavirenz, lamivudine, and tenofovir) in people who have both HIV and tuberculosis. It aims to find a treatment that works well and has fewer side effects.
This study looks at why some people with HIV on antiretroviral therapy still have small amounts of virus in their blood, while others achieve undetectable levels. Researchers will compare the two groups to understand the virus and immune system, which may help improve future treatments.
This study is testing three experimental antibodies (ePGT121v1-LS, PGDM1400LS, and VRC07-523LS) that may help prevent HIV. It’s looking at their safety and how long they stay in the body. Healthy volunteers without HIV can join.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
This study tests a new long-acting HIV medication taken by mouth that may allow you to switch from your current daily pill. It is for people who have had an undetectable HIV viral load for at least 6 months and are currently on a stable HIV treatment.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.